<p>/PRNewswire/ --2025 年 12 月 5 日，深圳微芯生物科技有限公司创始人兼董事长卢显平博士被评选为 2025 年安永年度企业家奖™中国大陆获奖者。</p>
<p>这一荣誉表彰了他在推动新质量生产力和推动制药行业创新方面的杰出贡献。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>卢显平博士在颁奖典礼上发表讲话。</p>
<p>本次奖项以&#34;二十年的坚定力量，迈向新时代&#34;为主题，庆祝那些肩负新时代责任并为国家繁荣和社会进步做出重大贡献的企业家。</p>
<p>卢显平博士是中国创新制药领域杰出的科学家和企业家。他获得了北京协和医学院的分子生物学博士学位，在美国进行博士后研究，并成功创办了两家生物制药公司。出于&#34;为普通人开发可负担的创新药物&#34;的使命，他选择回国，于 2001 年成立了微芯生物。</p>
<p>在中国历史上对仿制药的关注背景下，卢博士致力于研究具有全新作用机制的首创药物。通过建立基于化学基因组学和人工智能辅助设计的新药发现与评估平台，他显著提高了研发成功率并缩短了开发周期。在他的领导下，Chidamide 成为中国首个原创小分子抗肿瘤创新药物，也是中国首个全球许可的药品，填补了中国外周 T 细胞淋巴瘤治疗的关键空白，并为乳腺癌、成人 T 细胞白血病、弥漫大 B 细胞淋巴瘤等恶性肿瘤患者带来了新的希望。经过 19 年的研发，Chiglitazar Sodium 作为全球首个 PPAR 全激动剂，标志着 2 型糖尿病领域的历史性突破。这两种药物均已纳入中国国家医保药品目录（NRDL），大幅减轻了患者的经济负担。目前的研发管线中，多个具有显著首创潜力的药物候选者预计将为阿尔茨海默病等慢性疾病提供新的治疗选择。</p>
<p>卢博士积极推动中国制药生态系统的改善，包括创新药物审评路径的演变、NRDL 纳入机制和资本市场改革。在他的指导下，微芯生物已捐赠超过 7 亿人民币的药品，帮助超过 10,000 名患者减轻治疗费用。致力于开发具有新靶点、结构和机制的首创疗法，他被国际媒体誉为&#34;中国原创创新药物的先驱&#34;。</p>
<p>来源：深圳微芯生物科技有限公司。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3"/></p>

微芯生物

<p>深圳微芯生物创始人兼董事长卢显平博士被评选为 2025 年安永年度企业家奖™中国大陆获奖者。这一荣誉突显了他在制药行业创新方面的贡献。卢博士拥有分子生物学博士学位，于 2001 年创立微芯生物，致力于开发可负担的创新药物。他的领导下，创造了如奇达莫德和奇格利他钠等重要药物，改善了多种癌症和糖尿病的治疗选择。他还为提升中国的制药生态系统做出了贡献，并向患者捐赠了超过 7 亿人民币的药品</p>

<p>, /PRNewswire/ -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards.</p>
<div class="lb-trans"><p>/PRNewswire/ --2025 年 12 月 5 日，深圳微芯生物科技有限公司创始人兼董事长卢显平博士被评选为 2025 年安永年度企业家奖™中国大陆获奖者。</p>
</div><p>This recognition honors his outstanding contributions to advancing new-quality productive forces and driving innovation within the pharmaceutical industry.</p>
<div class="lb-trans"><p>这一荣誉表彰了他在推动新质量生产力和推动制药行业创新方面的杰出贡献。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Dr. Lu Xianping delivers his remarks at the award ceremony.</p>
<div class="lb-trans"><p>卢显平博士在颁奖典礼上发表讲话。</p>
</div><p>The award program, themed &#34;Two Decades of Unwavering Strength, Forging Ahead in the New Era,&#34; celebrates entrepreneurs who shoulder new-era responsibilities and contribute significantly to national prosperity and social progress.</p>
<div class="lb-trans"><p>本次奖项以&#34;二十年的坚定力量，迈向新时代&#34;为主题，庆祝那些肩负新时代责任并为国家繁荣和社会进步做出重大贡献的企业家。</p>
</div><p>Dr. Lu Xianping stands as a distinguished scientist and entrepreneur in China's innovative pharmaceutical sector. He earned a Ph.D. in Molecular Biology from Peking Union Medical College, pursued postdoctoral research in the U.S., and successfully founded two biopharmaceutical companies. Driven by the mission to &#34;develop affordable innovative drugs for ordinary people,&#34; he chose to return to China and established Chipscreen Biosciences in 2001.</p>
<div class="lb-trans"><p>卢显平博士是中国创新制药领域杰出的科学家和企业家。他获得了北京协和医学院的分子生物学博士学位，在美国进行博士后研究，并成功创办了两家生物制药公司。出于&#34;为普通人开发可负担的创新药物&#34;的使命，他选择回国，于 2001 年成立了微芯生物。</p>
</div><p>Against the backdrop of China's historical focus on generic drugs, Dr. Lu dedicated himself to researching first-in-class drugs with entirely novel mechanisms of action. By building a new drug discovery and evaluation platform based on chemical genomics and AI-assisted design, he significantly improved R&amp;D success rates and shortened development cycles. Under his leadership, Chidamide became China's first original small-molecule anti-tumor innovative drug and the country's first pharmaceutical product to be globally licensed out. It filled a critical gap in treating peripheral T-cell lymphoma in China and has extended new hope to patients with breast cancer, adult T-cell leukemia, diffuse large B-cell lymphoma and other malignancies. Chiglitazar Sodium, developed over 19 years for Type 2 diabetes, marked a historic breakthrough as the world's first PPAR pan-agonist. Both drugs have been included in China's National Reimbursement Drug List (NRDL), substantially reducing patients' financial burdens. In the current pipeline, multiple drug candidates with significant first-in-class potential are expected to deliver novel therapeutic options for chronic diseases such as Alzheimer's disease.</p>
<div class="lb-trans"><p>在中国历史上对仿制药的关注背景下，卢博士致力于研究具有全新作用机制的首创药物。通过建立基于化学基因组学和人工智能辅助设计的新药发现与评估平台，他显著提高了研发成功率并缩短了开发周期。在他的领导下，Chidamide 成为中国首个原创小分子抗肿瘤创新药物，也是中国首个全球许可的药品，填补了中国外周 T 细胞淋巴瘤治疗的关键空白，并为乳腺癌、成人 T 细胞白血病、弥漫大 B 细胞淋巴瘤等恶性肿瘤患者带来了新的希望。经过 19 年的研发，Chiglitazar Sodium 作为全球首个 PPAR 全激动剂，标志着 2 型糖尿病领域的历史性突破。这两种药物均已纳入中国国家医保药品目录（NRDL），大幅减轻了患者的经济负担。目前的研发管线中，多个具有显著首创潜力的药物候选者预计将为阿尔茨海默病等慢性疾病提供新的治疗选择。</p>
</div><p>Dr. Lu has actively promoted improvements in China's pharmaceutical ecosystem, including the evolution of innovative drug review pathways, NRDL inclusion mechanisms and capital market reforms. Under his guidance, Chipscreen has donated over RMB 700 million worth of medicines, helping more than 10,000 patients alleviate treatment costs. Dedicated to developing first-in-class therapies with novel targets, structures and mechanisms, he has been hailed by international media as &#34;China's pioneer of original innovative drugs.&#34;</p>
<div class="lb-trans"><p>卢博士积极推动中国制药生态系统的改善，包括创新药物审评路径的演变、NRDL 纳入机制和资本市场改革。在他的指导下，微芯生物已捐赠超过 7 亿人民币的药品，帮助超过 10,000 名患者减轻治疗费用。致力于开发具有新靶点、结构和机制的首创疗法，他被国际媒体誉为&#34;中国原创创新药物的先驱&#34;。</p>
</div><p>SOURCE Shenzhen Chipscreen Biosciences Co., Ltd.</p>
<div class="lb-trans"><p>来源：深圳微芯生物科技有限公司。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjI5Jk5ld3NJdGVtSWQ9Q041NDE5NyZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMjkxOTQ1UFJfTkVXU19VU1BSX19fX19DTjU0MTk3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN54197&amp;Transmission_Id=202512291945PR_NEWS_USPR_____CN54197&amp;DateId=20251229"/></p>

19:45 ET
			
			
				Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

微芯生物创始人兼董事长陆先平博士被评为安永 2025 年度企业家奖中国大陆地区获奖者